Damian Lamb
Co-Founder and Managing Director @ Genesys Capital
Damian Lamb is a Series A investor at Genesys Capital focused on Health Care and Biotechnology. Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $225 million in venture capital funds, and has been involved in deploying over $140million in 28 investments. He currently serves on the Boards of Affinium Pharmaceuticals Inc., Profound Medical Inc. and the Centre for Probe Development and Commercialization at McMaster University. He has served on the Board of Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences and was a judge for the BioNorth Top 10 Canadian Life Sciences Companies contest from 2000 to 2008.Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with an M.S. in Molecular Neurobiology and also holds an MBA from Queen's University.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Damian Lamb invests in
Stages Damian Lamb invests in
Countries Damian Lamb invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Affinium Pharmaceuticals
|
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property:issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway. | $18M / Series A / Mar 26, 2007 |
Co-Investors
About Genesys Capital
Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising biotechnology investment opportunities.
Genesys Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Damian Lamb
Co-Founder and Managing Director
|
|||
|
Jamie Stiff
Managing Director
|
|||
Jennifer Williams
Partner and CFO; Director of Finance and Operations
|
|||
Kelly Holman
Co-Founder and Managing Director
|
|||
Maxime Ranger
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Damian Lamb invest in?
Damian Lamb invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Damian Lamb last invest?
The most recent investment recorded for Damian Lamb closed in Mar 2007. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
